{"id":"abp-745-dose-c","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a bispecific antibody candidate from Atom Therapeutics, ABP-745 is designed to bind two different antigens or receptors simultaneously, enabling dual pathway modulation. This approach may enhance therapeutic efficacy by targeting complementary mechanisms or improving selectivity compared to monospecific antibodies. The specific targets and mechanism remain proprietary pending further clinical disclosure.","oneSentence":"ABP-745 is a bispecific antibody that simultaneously engages two distinct molecular targets to modulate immune or disease-related pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:28:29.530Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07303777","phase":"PHASE2","title":"Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2026-04","conditions":"Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":557,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABP-745 Dose C","genericName":"ABP-745 Dose C","companyName":"Atom Therapeutics Co., Ltd","companyId":"atom-therapeutics-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABP-745 Dose C is not mentioned in the provided facts, but ABP-745 Dose A and ABP-745 Dose B are being studied in a Phase II clinical trial for the treatment of Atherosclerosis, Cardiovascular Disease, and ASCVD. The study is evaluating the efficacy, safety, and pharmacokinetic profile of ABP-745 in patients with Atherosclerosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}